Home

Next Generation Vaccines for Multi-Resistant Bacteria

Mission

Discover and develop safe and effective vaccines to overcome infectious challenges threatening global public health


Vision

A world free of suffering from infectious diseases


Proxi Biotech's BACTOVAC platform technology offers superior vaccines to overcome the challenge of resistant bacteria


Antimicrobial resistance (AMR) is one of the world's most pressing medical problems. More than 700,000 people die each year from infections resistant to antibiotics. By 2050, such infections are expected to kill 10,000,000 people.


Proxi Biotech, an early stage spin-off from the Serum Institute of Denmark, has developed the BACTOVAC platform technology for detoxification of bacterial toxins. BACTOVAC overcomes main barriers of traditional vaccine developing technologies that allows new, highly needed vaccine to enter market and fight multi-resistant bacteria


News


Contact information


Nørre Allé 41

2200 Copenhagen


info@proxibiotech.com

Copyright 2019 Proxi Biotech All Rights Reserved